









Markets
/
Stocks
/
nasdaq-rdhl
/

Redhill Biopharma Ltd

RDHL

View Detailed Chart

1.190USD

-0.010-0.82%

Market hours （ET）Quotes delayed by 15 min

1.54MMarket Cap

0.13P/E TTM



Redhill Biopharma Ltd

1.190

-0.010-0.82%

Overview Company Financials

Financials

Intraday

30m

Today

-0.82%

5 Days

-30.40%

1 Month

-41.37%

6 Months

-79.76%

Year to Date

-80.83%

1 Year

-92.54%

View Detailed Chart

Agency Rating

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

15m

30m

15m

30m

D

Sell

Sell(9)

Neutral(1)

Buy(0)

Indicators

Sell(3)

Neutral(1)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.194

Sell

RSI(14)

32.455

Neutral

STOCH(KDJ)(9,3,3)

1.581

Oversold

ATR(14)

0.359

High Vlolatility

CCI(14)

-142.283

Sell

Williams %R

98.866

Oversold

TRIX(12,20)

-0.775

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

1.419

Sell

MA10

1.717

Sell

MA20

1.903

Sell

MA50

1.896

Sell

MA100

2.123

Sell

MA200

4.329

Sell

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

RedHill Biopharma Ltd is an Israel-based specialty biopharmaceutical company primarily focused on gastrointestinal and infectious diseases. RedHill promotes the gastrointestinal drugs such as, Talicia for the treatment of Helicobacter pylori (H. pylori) infection, and Aemcolo, for the treatment of travelers’ diarrhea. RedHill’s clinical late-stage development programs include: :info: RHB-204, for pulmonary nontuberculous mycobacteria (NTM) disease; opaganib (ABC294640), host-directed, SPHK2 inhibitor targeting multiple indications, RHB-107 (upamostat), an oral, host-directed serine protease inhibitor with potential for pandemic preparedness, is in late-stage development for treatment of non-hospitalized symptomatic COVID-19, and is targeting multiple other cancer and inflammatory gastrointestinal diseases; RHB-104 for Crohn's disease; and RHB-102 for chemotherapy and radiotherapy induced nausea and vomiting.

Ticker SymbolRDHL

CompanyRedhill Biopharma Ltd

CEOMr. Dror Ben-Asher

Websitehttps://www.redhillbio.com/